NCT06651398

Brief Summary

Bowel cleansing prior to colonoscopy is crucial to be able to perform a high-quality examination. Therefore maximum efforts are made to achieve optimal bowel cleansing including diet restriction and refraining from day-before dinner. However, the effect of this interdiction is currently not clear. On the other hand, patient compliance and experience with the entire procedure is important, especially for follow-up colonoscopies. Strict diets may interfere with this as an additional burden on the patient. In this study we want to assess whether a more lenient diet influences the quality of bowel preparation and whether it improves patient's experience.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
525

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Feb 2023

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 14, 2023

Completed
1.7 years until next milestone

First Submitted

Initial submission to the registry

October 18, 2024

Completed
3 days until next milestone

First Posted

Study publicly available on registry

October 21, 2024

Completed
11 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2024

Completed
Last Updated

October 21, 2024

Status Verified

October 1, 2024

Enrollment Period

1.7 years

First QC Date

October 18, 2024

Last Update Submit

October 18, 2024

Conditions

Keywords

bowel preparationcolonoscopy preparationbowel cleansing

Outcome Measures

Primary Outcomes (1)

  • Number of patients with an adequate bowel preparation (BBPS ≥6, and no segmental subscore ≤1)

    Max 12 weeks

Secondary Outcomes (4)

  • Number of patients with an optimal bowel preparation (BBPS 8-9)

    Max 12 weeks

  • Detection rates

    Max 12 weeks

  • Number of patients with high-quality right sided colon preparation (subscore = 3)

    Max 12 weeks

  • Overall patient's tolerance, adherence and satisfaction based on the patient's diary

    Max 12 weeks

Study Arms (2)

Lenient diet

EXPERIMENTAL

This group can have a less stringent diet compared to the current standard of care and eat a light meal until 18h before drinking the first dose of the bowel preparation on the day before the colonoscopy

Behavioral: Lenient diet

Control group

NO INTERVENTION

This group follows the strict diet similar to what is currently used in standard of care.

Interventions

Lenient dietBEHAVIORAL

The interventional goup receives the lenient diet instructions and will eat a light meal until 18h on the day before the colonoscopy. The first dose of Plenvu will be started at 20h. All the other bowel preparation instructions will be the same as in the control group.

Lenient diet

Eligibility Criteria

Age40 Years - 85 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient referred for diagnostic colonoscopy
  • Age between 40 and 85 years old
  • Ability of normal oral ingestion
  • Able to give informed consent by the patient or the legal representative

You may not qualify if:

  • Participant has a history of (partial) colectomy, excluding appendectomy
  • Inability of oral ingestion
  • Chronic severe constipation, defined as the need for daily laxative use of any kind or the need to use laxatives to obtain defaecation.
  • Uncontrolled coagulopathy
  • Pregnancy
  • Premenopausal women not adhering to any contraceptive method
  • Inflammatory bowel disease
  • Lynch syndrome
  • Familial adenomatosis polyposis syndrome
  • Serrated polyposis syndrome
  • hypersensitivity to the active substances of PLENVU as listed in the SmPC section 6.1
  • gastrointestinal obstruction or perforation
  • ileus
  • gastric emptying disorders (e.g. gastroparesis, gastric retention, etc.)
  • phenylketonuria (due to the presence of aspartame in PLENVU)
  • +4 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

UZ Leuven

Leuven, Vlaams-Brabant, 3000, Belgium

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
CARE PROVIDER, INVESTIGATOR
Masking Details
The endoscopist who performs the colonoscopy and the investigator who acts as second observer are blinded to objectively assess the BBPS.
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 18, 2024

First Posted

October 21, 2024

Study Start

February 14, 2023

Primary Completion

November 1, 2024

Study Completion

November 1, 2024

Last Updated

October 21, 2024

Record last verified: 2024-10

Locations